Processing

Please wait...

Settings

Settings

Goto Application

1. WO2008020802 - CARDIOPROTECTIVE COMPOUNDS

Publication Number WO/2008/020802
Publication Date 21.02.2008
International Application No. PCT/SE2007/000731
International Filing Date 17.08.2007
IPC
C07K 5/10 2006.01
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
KPEPTIDES
5Peptides having up to four amino acids in a fully defined sequence; Derivatives thereof
04containing only normal peptide links
10Tetrapeptides
C07K 5/107 2006.01
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
KPEPTIDES
5Peptides having up to four amino acids in a fully defined sequence; Derivatives thereof
04containing only normal peptide links
10Tetrapeptides
107the side chain of the first amino acid containing carbocyclic rings, e.g. Phe, Tyr
A61K 38/07 2006.01
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
38Medicinal preparations containing peptides
04Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
07Tetrapeptides
A61P 25/04 2006.01
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
25Drugs for disorders of the nervous system
04Centrally acting analgesics, e.g. opioids
A61P 9/10 2006.01
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
9Drugs for disorders of the cardiovascular system
10for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
CPC
A61K 38/00
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
38Medicinal preparations containing peptides
A61P 1/16
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
1Drugs for disorders of the alimentary tract or the digestive system
16for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
A61P 11/00
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
11Drugs for disorders of the respiratory system
A61P 25/04
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
25Drugs for disorders of the nervous system
04Centrally acting analgesics, e.g. opioids
A61P 25/28
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
25Drugs for disorders of the nervous system
28for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
A61P 27/02
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
27Drugs for disorders of the senses
02Ophthalmic agents
Applicants
  • ERIBIS PHARMACEUTICALS AB [SE]/[SE] (AllExceptUS)
  • BOBROVA, Irina [SE]/[SE] (UsOnly)
Inventors
  • BOBROVA, Irina
Agents
  • LIDÉN, Camilla
Priority Data
0601695-017.08.2006SE
Publication Language English (EN)
Filing Language English (EN)
Designated States
Title
(EN) CARDIOPROTECTIVE COMPOUNDS
(FR) COMPOSÉS CARDIOPROTECTEURS
Abstract
(EN)
Tissue protective compounds comprise the tetrapeptide structure A - B- C- D wherein each hydrogen of the N-terminus NH2 of amino acid residue A may independently optionally be replaced by C1-S alkyl or C1-S acyl, A - is an aromatic amino acid residue wherein the aromatic ring may optionally be substituted with one or more nitro group, B - is a diamino acid residue wherein the side chain amino group is substituted with C1-S acyl, C1-S alkyl, -B'-Ci-s acyl or -B'-Ci-s alkyl, wherein B' is an amino acid residue which may optionally be substituted with one or more nitro group, C - is GIy wherein the peptide N-H may optionally be changed to N-methyl, D - is Phe which is substituted on the aromatic ring with at least one nitro group and optionally further substituted on the aromatic ring with one or more group independently selected from nitro, fluoro, chloro, bromo, iodo, CF3 or CN, wherein the peptide N-H may optionally be changed to N-methyl, and the C-terminus C=O of amino acid residue D is substituted with NH2, NHC1-5 alkyl, NH-NH2, NH-NHC1-5 alkyl, or 0-C1-S alkyl, or the C-terminus is COOH or CH2OH, or a pharmaceutically acceptable salt thereof.
(FR)
La présente invention concerne des composés protecteurs des tissus comprenant la structure tétrapeptidique A - B - C - D dans laquelle: chaque hydrogène de l'extrémité N NH2 du résidu d'aminoacide A peut éventuellement être remplacé indépendamment par alkyle C1-5 ou acyle C1-5; A - représente un résidu d'aminoacide aromatique, le cycle aromatique pouvant éventuellement être substitué par un ou plusieurs groupes nitro; B - représente un résidu de diaminoacide, le groupe amino à chaîne latérale étant substitué par acyle C1-5, alkyle C1-5, acyle -B'-C1-5 ou alkyle -B'-C1-5, B' représentant un résidu d'aminoacide pouvant éventuellement être substitué par un ou plusieurs groupes nitro; C - représente Gly, le peptide N-H pouvant éventuellement être changé en N-méthyle; D - représente Phe substitué sur le cycle aromatique par au moins un groupe nitro et éventuellement également substitué sur le cycle aromatique par un ou plusieurs groupes indépendamment sélectionnés parmi nitro, fluoro, chloro, bromo, iodo, CF3 ou CN, le peptide N-H pouvant éventuellement être changé en N-méthyle; l'extrémité C C=O du résidu d'aminoacide D est substituée par NH2, alkyle NHC1-5, NH-NH2, alkyle NH-NHC1-5, ou alkyle O-C1-5, ou l'extrémité C est COOH ou CH2OH; ou un sel pharmaceutiquement acceptable de celui-ci.
Latest bibliographic data on file with the International Bureau